News Archive

The Cedars-Sinai accelerator, managed by Techstars, kicked off its third class of healthcare startups this month. some of which are more mature than previous cohorts with a seed stage round behind them. Whittled down from roughly 600 applicants, the 10 companies are seeking to improve the patient experience, offer more personalized care plans for cancer treatment, triage faster and make blood sample collection less painful. Their technologies span artificial intelligence, voice recognition, microfluidics, and natural language processing.

Larger medtech companies have traditionally shied away from investing in the pediatric market, but the landscape is changing. In the last year alone, we witnessed the passage of the 21st Century Cures Act and the signing of the FDA Reauthorization Act (FDARA 2017) into law. The industry is ripe for innovation and these legislative advances present new opportunities to connect innovators with the investment community.

One week until Beta City! Join Betamore + Sagamore Ventures on September 28 for Maryland’s annual celebration of entrepreneurship + technology. Beta City brings together Baltimore’s greatest minds for a day full of pitches, startup demos and a celebration of our growing community.

Thursday September 28, 2017 6:00 PM – 8:00 PM

Brewer’s Alley 124 North Market Street Frederick, MD 21701

Leave the stress of your work day behind and come join friends and colleagues at MTC’s Young Professionals Society networking event. Join us in Frederick for light hors d’oeuvres and a cash bar. 

YPS advances young professionals through leadership and professional development, networking opportunities, educational events and community outreach. The society strengthens the life science and technology communities in Maryland by providing an opportunity for collaboration among these two industries.

This group is designed for MTC members 35 years and under. We look forward to seeing you soon!

Greater Washington has no shortage of respected leaders, and some of them are among the world’s most revered.

Welcome to ARP Network Quarterly Notes! Our goal is to keep you informed about ARP Network and Agricultural Research Service’s current information. We hope that the notes build networking opportunities for businesses to connect with ARP Network Members. Please help us spread the word by sharing ARP Network Notes statewide with your company contacts, colleagues, other organizations, etc. Thank you!

What is Philips HealthWorks? As a venture capital fund, what qualities do you look for in a partner?

While the Philips HealthWorks team is linked to our Health Technology Venture Fund team at Philips, we see ourselves, first and foremost, as defining a new model for innovation community engagement. Think of Philips HealthWorks as a new front door for early-stage companies to collaborate with our global company.

The Emmes Corporation today announced that it is the new corporate sponsor of Leadership Montgomery’s Corporate Volunteer Council. 

The grant from Emmes will help Leadership Montgomery add new business partners, help existing partners increase the number of employee volunteers, and match volunteer interests with the needs of area non-profit and charitable organizations.

Institute for Bioscience & Biotechnology Research 9600 Gudelsky Drive Rockville, MD, Maryland 20850

Wednesday, October 4, 2017 from 6:00 PM to 8:00 PM (EDT)

As physicians, scientists and entrepreneurs, sometimes we believe that we can do it all, only to find out that our attempts at practicing law, accounting or financial strategy are many times misguided. Come and learn from experts in the field about the obstacles and opportunities that are ahead of you and how best to navigate these choppy waters!

CEL-SCI Corporation (NYSE American: CVM) announced today that it has been awarded a new Phase II Small Business Innovation Research (SBIR) grant by the National Institute of Arthritis and Musculoskeletal and Skin Diseases entitled “Preclinical studies of PG70 LEAPS peptide vaccine for rheumatoid arthritis”. The grant in the amount of approximately $1.5 million will provide funding to allow CEL-SCI to advance its first LEAPS product candidate, CEL-4000, towards an Investigational New Drug (IND) application, by funding GMP manufacturing, IND enabling studies, and additional mechanism of action studies.